drugset / Trial / NCT07153952
RT for Adenocarcinoma/Adenosquamous Carcinoma
Phase 1/2
Active not recruiting
60 enrolled
Peking Union Medical College Hospital
Heilongjiang Provicial Hospital · collabLiaoning Cancer Hospital & Institute · collabLuohe Central Hospital · collabObstetrics and Gynecology Hospital of Zhejiang University · collabThe First Affiliated Hospital of Xiamen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to establish a prospective cohort of locally advanced cervical adenocarcinoma to provide a better way to monitor its efficacy and provide precise treatment. The key problems to be solved are as follows: 1. Establish an observational prospective cohort of locally advanced ADC and randomly divide patients with residual cervical tumors in the primary site after CCRT into the local treatment group (salvage surgery or supplementary radiotherapy) or the systemic treatment group. 2. Collect cervical biopsy tissues before and after CCRT in patients with residual cervical tumors, explore the genomic characteristics, and predict whether they can benefit from targeted/immunotherapy in the future.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2027-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Neratinib | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | apelisimab | Unknown | — | — |